Mildly decreased preoperative bilirubin levels are associated with infections after shoulder and knee arthroplasty.
C-reactive protein
arthroplasty
bilirubin
infection
total joint replacement
Journal
Journal of orthopaedic research : official publication of the Orthopaedic Research Society
ISSN: 1554-527X
Titre abrégé: J Orthop Res
Pays: United States
ID NLM: 8404726
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
27
09
2019
revised:
17
01
2020
accepted:
30
01
2020
pubmed:
6
2
2020
medline:
15
12
2020
entrez:
5
2
2020
Statut:
ppublish
Résumé
Increasing numbers of arthroplasties are also accompanied by postoperative infections. The main purpose was to evaluate preoperative serum bilirubin levels between patients with and without infections after shoulder and knee arthroplasties. For this retrospective case-control single-center study, a total of 108 patients were extracted from a prospectively collected database. Eighteen patients with infections after shoulder (n = 8) and knee (n = 10) arthroplasty were matched by age, gender, and implant type in a 1:5-scenario to 90 patients (40 shoulders and 50 knees) without postoperative infection. Demographic data, preoperative blood parameters, and postoperative infection-related outcomes were evaluated. Total bilirubin was the only preoperative parameter significantly different between the infection (8.21 ± 3.25 μmol/L or 0.48 ± 0.19 mg/dL) and noninfection (10.78 ± 4.62 μmol/L or 0.63 ± 0.27 mg/dL; P = .014) group, while C-reactive protein and other liver parameters were similar between the groups. Significantly more controls (92.1%) had preoperative bilirubin levels above 8.72 μmol/L or 0.51 mg/dL than cases (7.9%; P = .007). The 5-year infection survival-rate was 65.6% for patients with preoperative bilirubin levels < 8.72 μmol/L or < 0.51 mg/dL and 91.2% with ≥ 8.72 μmol/L or ≥ 0.51 mg/dL. Mildly decreased preoperative bilirubin levels with a cutoff at 8.72 μmol/L or 0.51 mg/dL were significantly associated to patients with infections after shoulder and knee arthroplasty. There were no differences in other blood parameters or comorbidities between patients with infections and their matched-controls.
Substances chimiques
Bilirubin
RFM9X3LJ49
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2074-2082Informations de copyright
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
Références
Singh JA. Epidemiology of knee and hip arthroplasty: a systematic review. Open Orthop J. 2011;5(1):80-85.
Kim SH, Wise BL, Zhang Y, Szabo RM. Increasing incidence of shoulder arthroplasty in the United States. J Bone Joint Surg. 2011;93(24):2249-2254.
Toms AD. The management of peri-prosthetic infection in total joint arthroplasty. J Bone Joint Surg [Br]. 2006;88-B(2):149-155.
Bonnevialle N, Dauzères F, Toulemonde J, Elia F, Laffosse JM, Mansat P. Periprosthetic shoulder infection: an overview. EFORT Open Rev. 2017;2(4):104-109.
Akgün D, Müller M, Perka C, Winkler T. The serum level of C-reactive protein alone cannot be used for the diagnosis of prosthetic joint infections, especially in those caused by organisms of low virulence. Bone Joint J. 2018;100B(11):1482-1486.
Wagner K-H, Wallner M, Mölzer C, et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clin Sci (Lond). 2015;129(1):1-25.
Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol. 2004;66(4):773-779.
Arai T, Yoshikai Y, Kamiya J, et al. Bilirubin impairs bactericidal activity of neutrophils through an antioxidant mechanism in vitro. J Surg Res. 2001;96(1):107-113.
Weinberger B, Archer FE, Kathiravan S, et al. Effects of bilirubin on neutrophil responses in newborn infants. Neonatology. 2013;103(2):105-111.
Seyed Khoei N, Grindel A, Wallner M, et al. Mild hyperbilirubinaemia as an endogenous mitigator of overweight and obesity: implications for improved metabolic health. Atherosclerosis. 2018;269:306-311.
Abbasi A, Deetman PE, Corpeleijn E, et al. Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. Diabetes. 2015;64(4):1459-1469.
Ong K-L, Allison MA, Cheung BMY, Wu BJ, Barter PJ, Rye K-A. The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004. PLoS One. 2014;9(4):e94479. https://doi.org/10.1371/journal.pone.0094479
Horsfall LJ, Rait G, Walters K, et al. Serum bilirubin and risk of respiratory disease and death. JAMA. 2011;305(7):691-697.
Horsfall LJ, Nazareth I, Pereira SP, Petersen I. Gilbert's syndrome and the risk of death: a population-based cohort study. J Gastroenterol Hepatol. 2013;28(10):1643-1647.
Vitek L, Hubacek JA, Pajak A, et al. Association between plasma bilirubin and mortality. Ann Hepatol. 2019;18(2):379-385.
Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3(3):55. https://doi.org/10.3389/fphar.2012.00055 eCollection.
Saleh A, George J, Faour M, Klika AK, Higuera CA. Serum biomarkers in periprosthetic joint infections. Bone Joint Res. 2018;7(1):85-93.
Berbari E, Mabry T, Tsaras G, et al. Inflammatory blood laboratory levels as markers of prosthetic joint infection: a systematic review and meta-analysis. J Bone Joint Surg [Am]. 2010;92(11):2102-2109.
Windisch C, Brodt S, Roehner E, Matziolis G. C-reactive protein course during the first 5 days after total knee arthroplasty cannot predict early prosthetic joint infection. Arch Orthop Trauma Surg. 2017;137(8):1115-1119.
Pfitzner T, Krocker D, Perka C, Matziolis G. Das C-reaktive protein. Ein unabhängiger risikofaktor für die entwicklung eines infekts nach primärendoprothetik. Orthopade. 2008;37(11):1116-1120.
Ettinger M, Calliess T, Kielstein JT, et al. Circulating biomarkers for discrimination between aseptic joint failure, low-grade infection, and high-grade septic failure. Clin Infect Dis. 2015;61(3):332-341.
Glehr M, Friesenbichler J, Hofmann G, et al. Novel biomarkers to detect infection in revision hip and knee arthroplasties infection. Clin Orthop Relat Res. 2013;471(8):2621-2628.
Bottner F, Wegner A, Winkelmann W, Becker K, Erren M, Götze C. Interleukin-6, procalcitonin and TNF-α: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg [Br]. 2007;89-B(1):94-99.
Randau TM, Friedrich MJ, Wimmer MD, et al. Interleukin-6 in serum and in synovial fluid enhances the differentiation between periprosthetic joint infection and aseptic loosening. PLoS One. 2014;9(2):1-6.
Friedrich MJ, Randau TM, Wimmer MD, et al. Lipopolysaccharide-binding protein: a valuable biomarker in the differentiation between periprosthetic joint infection and aseptic loosening? Int Orthop. 2014;38(10):2201-2207.
Shahi A, Kheir MM, Tarabichi M, Hosseinzadeh HRS, Tan TL, Parvizi J. Serum D-dimer test is promising for the diagnosis of periprosthetic joint infection and timing of reimplantation. J Bone Joint Surg [Am]. 2017;99(17):1419-1427.
Wallner M, Bulmer AC, Mölzer C, et al. Haem catabolism: a novel modulator of inflammation in Gilbert's syndrome. Eur J Clin Invest. 2013;43(9):912-919.
Mölzer C, Wallner M, Kern C, et al. Characteristics of the heme catabolic pathway in mild unconjugated hyperbilirubinemia and their associations with inflammation and disease prevention. Sci Rep. 2017;7(1):1-15.
Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012;126(22):2556-2564.
Kawamoto R, Ninomiya D, Hasegawa Y, et al. Mildly elevated serum bilirubin levels are negatively associated with carotid atherosclerosis among elderly persons. PLoS One. 2014;9(12):1-14.
Nano J, Muka T, Cepeda M, et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes: a systematic review and meta-analysis of observational evidence. Diabetes Metab. 2016;42(6):389-397.
Higuchi S, Kabeya Y, Uchida J, Kato K, Tsukada N. Low bilirubin levels indicate a high risk of cerebral deep white matter lesions in apparently healthy subjects. Sci Rep. 2018;8(1):1-5.
Bian LQ, Li RZ, Zhang ZY, et al. Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. J Bone Miner Metab. 2013;31(6):637-643.
Juping D, Yuan Y, Shiyong C, et al. Serum bilirubin and the risk of rheumatoid arthritis. J Clin Lab Anal. 2017;31(6):1-6.
Bisht K, Tampe J, Shing C, et al. Endogenous tetrapyrroles influence leukocyte responses to lipopolysaccharide in human blood: pre-clinical evidence demonstrating the anti-inflammatory potential of biliverdin. J Clin Cell Immunol. 2014;30(5):1000218.
Terzi HA, Kardes H, Atasoy AR, et al. The antibacterial effects of bilirubin on gram-negative bacterial agents of sepsis. Biomed Res India. 2016;27(1):207-209.
Wu BJ, Chen K, Barter PJ, Rye K-A. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation. 2012;125(1):150-158.
Patel JJ, Taneja A, Niccum D, Kumar G, Jacobs E, Nanchal R. The association of serum bilirubin levels on the outcomes of severe sepsis. J Intensive Care Med. 2015;30(1):23-29.
Lakomkin N, Sathiyakumar V, Dodd AC, et al. Pre-operative labs: wasted dollars or predictors of post-operative cardiac and septic events in orthopaedic trauma patients? Injury. 2016;47(6):1217-1221.